Targeted Multiple Myeloma Treatment Melflufen Shows Efficacy for Difficult-to-Treat Triple-Class Refractory Disease
The targeted peptide-drug conjugate melflufen has shown efficacy for the treatment of triple-class refractory multiple myeloma.
Cancer
Biocept Reports Publication Further Validating Cancer-Detecting Liquid Biopsy Platform
Biocept, Inc. (Nasdaq: BIOC) has announced a clinical research publication further validating its cancer-detecting liquid biopsy platform.
Complete Response of Metastatic Pancreatic Cancer to Novel Immunotherapy
A novel immunotherapy approach combining natural killer cells with the cytokine IL-15 has led to a complete response of metastatic pancreatic cancer.
Sunesis Announces Phase 1b/2 Trial Data for B-Cell Malignancy Therapy
San Francisco-based biopharmaceutical company Sunesis announced phase 1b/2 clinical trial data for the non-covalent inhibitor of Bruton’s tyrosine kinase, Vecabrutinib.
Novel Engineered Nanoparticles Enhance Targeted Immunotherapy for Solid Tumors
Novel engineered nanoparticles have the ability to selectively deliver immune checkpoint blockade (ICB) therapy to tumors, allowing for targeted immunotherapy that is more efficient and has reduced side effects.
New Insights into Tumor-Associated Monocytes and Macrophages Show Promise for the Treatment of Breast and Endometrial Cancers
The unique transcriptional profiles of tumor-associated macrophages and their progenitors, tumor-educated monocytes, have been used to develop diagnostic/prognostic gene signatures for breast and endometrial cancers and suggest potent therapeutic targets.
Therapy for Steroid-Refractory and/or Resistant GvHD Favorably Alters White Blood Cell Profile
A therapy for steroid-refractory and/or resistant GvHD may function by favorably altering a population of circulating white blood cells.
Possible Combination Treatment for Patients with Cancers not Responsive to Immune Checkpoint Inhibitors
A combination treatment involving a drug stimulating an innate immune receptor could render immune checkpoint inhibitors functional in patients with otherwise unresponsive cancers.
CAR T Cells Show Efficacy for the Treatment of Relapsed and/or Refractory Aggressive Large B Cell Lymphoma
CAR T cells continue to show efficacy for the treatment of relapsed and/or refractory large B cell lymphoma.